LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Sugasaki, Nanae"
  2. AU="Khorrami, Arash"

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Fluctuation of Hepatic Focal Nodular Hyperplasia Size with Oral Contraceptives Use.

    Fukahori, Susumu / Kawano, Tetsuya / Obase, Yasushi / Umeyama, Yasuhiro / Sugasaki, Nanae / Kinoshita, Akitoshi / Fukushima, Chizu / Yamakawa, Masaki / Omagari, Katsuhisa / Mukae, Hiroshi

    The American journal of case reports

    2019  Volume 20, Page(s) 1124–1127

    Abstract: BACKGROUND Focal nodular hyperplasia (FNH) of the liver is a rare benign nodular lesion that arises in women of reproductive age. Although a role of female hormones has been suggested, their influence on the course of FNH has remained controversial. CASE ...

    Abstract BACKGROUND Focal nodular hyperplasia (FNH) of the liver is a rare benign nodular lesion that arises in women of reproductive age. Although a role of female hormones has been suggested, their influence on the course of FNH has remained controversial. CASE REPORT A 44-year-old woman with a 12-year history of oral contraceptive use was referred to our hospital for examination of an asymptomatic liver mass (3 cm in diameter) identified by computed tomography. We diagnosed FNH using imaging methods and fine-needle biopsy. Oral contraceptives were discontinued because the mass increased over a period of 21 months. Four months later, the mass had decreased in size, indicating that FNH can spontaneously regress when oral contraceptives are discontinued. CONCLUSIONS Discontinuation of oral contraceptives use can reduce the size of FNH, as in this case.
    MeSH term(s) Adult ; Contraceptives, Oral/adverse effects ; Female ; Focal Nodular Hyperplasia/chemically induced ; Focal Nodular Hyperplasia/diagnostic imaging ; Humans ; Magnetic Resonance Imaging ; Radionuclide Imaging ; Tomography, X-Ray Computed
    Chemical Substances Contraceptives, Oral
    Language English
    Publishing date 2019-07-30
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2517183-5
    ISSN 1941-5923 ; 1941-5923
    ISSN (online) 1941-5923
    ISSN 1941-5923
    DOI 10.12659/AJCR.916398
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.

    Tomono, Hiromi / Taniguchi, Hirokazu / Fukuda, Minoru / Ikeda, Takaya / Nagashima, Seiji / Akagi, Kazumasa / Ono, Sawana / Umeyama, Yasuhiro / Shimada, Midori / Gyotoku, Hiroshi / Takemoto, Shinnosuke / Hisamatsu, Yasushi / Morinaga, Ryotaro / Tagawa, Ryuta / Ogata, Ryosuke / Dotsu, Yosuke / Senju, Hiroaki / Soda, Hiroshi / Nakatomi, Katsumi /
    Hayashi, Fumiko / Sugasaki, Nanae / Kinoshita, Akitoshi / Mukae, Hiroshi

    Thoracic cancer

    2023  Volume 14, Issue 28, Page(s) 2890–2894

    Abstract: Introduction: Combined treatment using anti-programmed death-ligand 1 antibody (anti-PD-L1) and platinum-etoposide is the current standard first-line treatment for patients with extensive-stage (ES) small cell lung cancer (SCLC). However, the best ... ...

    Abstract Introduction: Combined treatment using anti-programmed death-ligand 1 antibody (anti-PD-L1) and platinum-etoposide is the current standard first-line treatment for patients with extensive-stage (ES) small cell lung cancer (SCLC). However, the best treatment for relapsed ES-SCLC after the first-line treatment remains unclear. There are some approved chemotherapeutic agents that can be used against ES-SCLC, and treatment with irinotecan is well established as both a monotherapy and a combined therapy, in combination with platinum. Therefore, we conduct a phase II study with irinotecan in the second- or later-line setting for patients with ES-SCLC who have been previously treated with combined treatment.
    Methods: Our study will enroll total 30 patients who are diagnosed with ES-SCLC and have experienced disease progression after the combined treatment. Patients will receive irinotecan on days 1, 8, and 15, which will be repeated every 4 weeks. Doses of irinotecan (100/80/60 mg/m
    Discussion: Since the present first-line treatment has been changed to the combined treatment, the second- or later-line treatment should be re-evaluated for patients with relapsed SCLC. Irinotecan is a major chemotherapeutic agent used for SCLC. This study demonstrates and re-evaluates the clinical benefits of irinotecan after combined treatment with anti-PD-L1 and platinum-etoposide for patients with ES-SCLC.
    Registration details: This study was registered in the Japan Registry of Clinical Trials (no. jRCT s071210090) on November 4, 2021.
    MeSH term(s) Humans ; Small Cell Lung Carcinoma ; Irinotecan/pharmacology ; Irinotecan/therapeutic use ; Etoposide ; Lung Neoplasms ; Platinum/therapeutic use ; Cisplatin/therapeutic use ; Camptothecin/therapeutic use ; Camptothecin/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/etiology ; Immunotherapy ; Disease Progression ; Clinical Trials, Phase II as Topic
    Chemical Substances Irinotecan (7673326042) ; Etoposide (6PLQ3CP4P3) ; Platinum (49DFR088MY) ; Cisplatin (Q20Q21Q62J) ; Camptothecin (XT3Z54Z28A)
    Language English
    Publishing date 2023-09-07
    Publishing country Singapore
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2625856-0
    ISSN 1759-7714 ; 1759-7706
    ISSN (online) 1759-7714
    ISSN 1759-7706
    DOI 10.1111/1759-7714.15097
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6921: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.

    Takemoto, Shinnosuke / Akagi, Kazumasa / Ono, Sawana / Tomono, Hiromi / Honda, Noritaka / Suyama, Takayuki / Umeyama, Yasuhiro / Dotsu, Yosuke / Taniguchi, Hirokazu / Ogawara, Daiki / Senju, Hiroaki / Gyotoku, Hiroshi / Sugasaki, Nanae / Yamaguchi, Hiroyuki / Nakatomi, Katsumi / Fukuda, Minoru / Mukae, Hiroshi

    Thoracic cancer

    2021  Volume 12, Issue 17, Page(s) 2300–2306

    Abstract: Background: S-1 and pemetrexed (PEM) are key treatments for non-small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S-1 and PEM is similar. Cross-resistance between S-1 and PEM is of concern. This exploratory study was ... ...

    Abstract Background: S-1 and pemetrexed (PEM) are key treatments for non-small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S-1 and PEM is similar. Cross-resistance between S-1 and PEM is of concern. This exploratory study was designed to evaluate the treatment effect of S-1 following PEM-containing treatment.
    Methods: This retrospective study included patients with advanced (c-stage III or IV, UICC seventh edition) or recurrent NSCLC who received S-1 monotherapy following the failure of previous PEM-containing chemotherapy at six hospitals in Japan. The primary endpoint of the study was the overall response rate (ORR). The secondary endpoint was the disease control rate (DCR), time to treatment failure (TTF), progression-free survival (PFS), and overall survival (OS).
    Results: A total of 53 NSCLC patients met the criteria for inclusion in the study. Forty-six patients had adenocarcinoma (88.7%) and no patients had squamous cell carcinoma. Thirty-one patients (58.5%) received the standard S-1 regimen and 18 patients (34.0%) received the modified S-1 regimen. ORR was 1.9% (95% confidence interval [CI]: 0.00%-10.1%). Median TTF, PFS, and OS were 65, 84, and 385 days, respectively.
    Conclusions: Although there were several limitations in this study, the ORR of S-1 after PEM in patients with nonsquamous (non-SQ) NSCLC was low compared to the historical control. One of the options in the future might be to avoid S-1 treatment in PEM-treated patients who need tumor shrinkage.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/therapeutic use ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Disease-Free Survival ; Drug Combinations ; Female ; Humans ; Lung Neoplasms/drug therapy ; Male ; Middle Aged ; Oxonic Acid/therapeutic use ; Pemetrexed/therapeutic use ; Retrospective Studies ; Tegafur/therapeutic use
    Chemical Substances Antimetabolites, Antineoplastic ; Antineoplastic Agents ; Drug Combinations ; Pemetrexed (04Q9AIZ7NO) ; S 1 (combination) (150863-82-4) ; Tegafur (1548R74NSZ) ; Oxonic Acid (5VT6420TIG)
    Language English
    Publishing date 2021-07-13
    Publishing country Singapore
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2625856-0
    ISSN 1759-7714 ; 1759-7706
    ISSN (online) 1759-7714
    ISSN 1759-7706
    DOI 10.1111/1759-7714.14055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6921: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.

    Mizoguchi, Kosuke / Nakamura, Yoichi / Sano, Kazumi / Sato, Shuntaro / Ikegami, Yoji / Motoshima, Kohei / Takemoto, Shinnosuke / Ogawara, Daiki / Senju, Hiroaki / Sugasaki, Nanae / Ikeda, Takaya / Yamaguchi, Hiroyuki / Nakatomi, Katsumi / Fukuda, Minoru / Izumikawa, Koichi / Mukae, Hiroshi

    Cancer chemotherapy and pharmacology

    2016  Volume 78, Issue 2, Page(s) 377–382

    Abstract: Purpose: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.: Patients and methods: ... ...

    Abstract Purpose: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.
    Patients and methods: Plasma trough levels of gefitinib were measured on days 2 (D2) and 8 (D8) by high-performance liquid chromatography in 31 patients. Plasma concentrations of gefitinib were also measured 10 h after the first administration in 21 of these patients to calculate the elimination half-life of gefitinib.
    Results: The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8. The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h. The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days. A high D8/D2 ratio was significantly correlated with better PFS, though the plasma trough levels on D2 and D8 were not significantly related to PFS. The elimination half-life was not a significant factor for PFS, but it was significantly correlated with high-grade adverse events. Pharmacokinetic parameters were not significantly correlated with OS.
    Conclusions: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. On the other hand, long elimination half-life was related to high-grade adverse events in these patients. Clinical Trial Registration UMIN000001066.
    MeSH term(s) Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Chromatography, High Pressure Liquid/methods ; Disease-Free Survival ; Female ; Half-Life ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Quinazolines/pharmacokinetics ; Receptor, Epidermal Growth Factor/genetics ; Survival Rate
    Chemical Substances Antineoplastic Agents ; Quinazolines ; Receptor, Epidermal Growth Factor (EC 2.7.10.1) ; gefitinib (S65743JHBS)
    Language English
    Publishing date 2016-08
    Publishing country Germany
    Document type Clinical Trial ; Journal Article
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/s00280-016-3097-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1420: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer.

    Taniguchi, Hirokazu / Yamaguchi, Hiroyuki / Dotsu, Yosuke / Shimada, Midori / Gyotoku, Hiroshi / Senju, Hiroaki / Takemoto, Shinnosuke / Kitazaki, Takeshi / Fukuda, Masaaki / Ogawara, Daiki / Soda, Hiroshi / Nakatomi, Katsumi / Sugasaki, Nanae / Kinoshita, Akitoshi / Nagashima, Seiji / Ikeda, Takaya / Nakamura, Yoichi / Sakamoto, Noriho / Obase, Yasushi /
    Fukuda, Minoru / Mukae, Hiroshi

    Thoracic cancer

    2019  Volume 10, Issue 9, Page(s) 1764–1769

    Abstract: Background: The first-line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach for ...

    Abstract Background: The first-line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach for patients with SCC. Therefore, a phase II study of this chemotherapeutic combination was designed to evaluate its efficacy and safety for treatment-naïve patients with advanced SCC.
    Methods: A total of 21 treatment-naïve patients with stage IIIB/IV or postoperative recurrent SCC were enrolled from six institutions. Nedaplatin (100 mg/m
    Results: Partial response was observed in seven of 21 cases (ORR, 33.3%; 95% confidence interval [CI], 14.5-52.2). Disease control rate, which includes stable disease, was 71.4%. Median OS and PFS was 14.6 and 4.1 months, respectively. This regimen did not cause any treatment-related deaths. Grade 3/4 neutropenia developed in 8 of 21 cases (38.1%); however, febrile neutropenia developed in only 9.5% of the cases. Grade 3/4 gastrointestinal or neuromuscular toxicities were not observed.
    Conclusion: The efficacy of the combination of nedaplatin and amrubicin was comparable to that of other conventional chemotherapeutic regimens for treatment-naïve patients with advanced SCC, and no severe gastrointestinal or neuromuscular toxicities were observed. This combination therapy may be an alternative treatment approach, particularly in patients who cannot tolerate gastrointestinal or neuromuscular toxicities.
    MeSH term(s) Aged ; Anthracyclines/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/pathology ; Drug-Related Side Effects and Adverse Reactions ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Organoplatinum Compounds/administration & dosage ; Prognosis ; Survival Rate
    Chemical Substances Anthracyclines ; Organoplatinum Compounds ; nedaplatin (8UQ3W6JXAN) ; amrubicin (93N13LB4Z2)
    Language English
    Publishing date 2019-07-16
    Publishing country Singapore
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study
    ZDB-ID 2625856-0
    ISSN 1759-7714 ; 1759-7706
    ISSN (online) 1759-7714
    ISSN 1759-7706
    DOI 10.1111/1759-7714.13134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6921: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top